Recombinant DNA Technology Market Growth Forecast: Market Size, Key Trends And Emerging Opportunities Through 2030
Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Recombinant DNA Technology Market Forecast: Value Set To Climb From $998.83 Billion To $1414.92 Billion
The recombinant dna technology market size has seen robust expansion in recent years. It is anticipated to increase from $913.42 billion in 2025 to $998.83 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.4%. The growth observed in the preceding period can be attributed to several factors including the expansion of molecular biology research, a rising incidence of chronic diseases, advances in biologics development, increased academic and government research funding, and the early commercialization of recombinant therapies.
The recombinant DNA technology market is projected to witness robust expansion in the coming years. Its valuation is set to climb to $1414.92 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.1%. This anticipated growth within the forecast period is driven by factors such as increasing investments in gene therapy development, a rising demand for personalized medicine, the broadening of CRISPR-based applications, a growing focus on sustainable bioproduction, and enhanced collaboration between academia and industry. Significant trends expected during this period include a greater adoption of gene editing platforms, an increase in the development of recombinant vaccines, the expanding utilization of advanced expression systems, an enlargement of cell and gene therapy pipelines, and a heightened emphasis on scalable biomanufacturing.
Get A Free Sample Report With In-Depth Market Insights:
Recombinant DNA Technology Market Growth Factors Behind Sustained Expansion
The increasing creation of genetically modified crops is projected to stimulate the expansion of the recombinant DNA technology market going forward. Genetically modified crops are defined as plants whose genetic composition has been purposefully altered using advanced biotechnological methods. Recombinant DNA (rDNA) technology finds application in genetically modified (GM) crops through a process that includes isolating genes for desired characteristics, assembling recombinant DNA, inserting it into recipient crop cells, screening for successful integration, propagating transgenic plants, assessing trait expression, conducting field experiments, securing necessary regulatory endorsements, and ultimately launching crops with improved attributes commercially. For example, in December 2023, according to the United States Department of Agriculture, a US-based government agency, Canada sowed 11.7 million hectares of genetically engineered (GE) crops, mainly consisting of canola, soybeans, and corn. This indicated a 4% rise from 2022, primarily driven by the growth in canola planting areas. Thus, the escalating development of genetically modified crops is propelling the growth of the recombinant DNA technology market.
Recombinant DNA Technology Market Segment Analysis And Revenue Potential
The recombinant dna technology market covered in this report is segmented –
1) By Product Type: Recombinant Protein Drugs, Vaccines, Genetically Modified Crops, Expression Systems, Cell And Gene Therapy, Gene Editing
2) By Component Type: Expression System, Cloning Vector
3) By Application Type: Food And Agriculture, Health And Disease, Environment, Other Application Types
4) By End-Use Type: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Other End-Use Types
Subsegments:
1) By Recombinant Protein Drugs: Hormones, Growth Factors
2) By Vaccines: Recombinant Viral Vaccines, Recombinant Bacterial Vaccines, Subunit Vaccines
3) By Genetically Modified Crops: Herbicide-Tolerant Crops, Insect-Resistant Crops, Nutritionally Enhanced Crop
4) By Expression Systems: Bacterial Expression Systems, Yeast Expression Systems, Mammalian Expression Systems
5) By Cell And Gene Therapy: Cell-Based Therapies, Gene Replacement Therapies, CAR T-Cell Therapies
6) By Gene Editing: CRISPR Or Cas9 Technologies, TALENs (Transcription Activator-Like Effector Nucleases), ZFNs (Zinc Finger Nucleases)
Recombinant DNA Technology Market Industry Trends Fueling Future Revenue Growth
Major companies operating in the recombinant DNA technology market are increasingly focusing on incorporating advanced gene-editing techniques like clustered regularly interspaced short palindromic repeats (CRISPR)-based recombinant DNA engineering to improve precision, therapeutic efficacy, and targeted genome modification. CRISPR-based recombinant DNA engineering is a molecular method that utilizes a guide RNA and the Cas9 enzyme to locate and cut specific DNA sequences, facilitating targeted gene correction, controlled DNA insertion, and efficient genomic modification. For instance, in December 2023, Vertex Pharmaceuticals, a US-based biotechnology company, along with CRISPR Therapeutics, a Switzerland-based gene-editing biotechnology company, obtained approval from the US Food and Drug Administration for Casgevy, a CRISPR-enabled recombinant DNA therapy developed for the treatment of sickle cell disease and transfusion-dependent beta thalassemia by editing a patient’s own stem cells to increase fetal hemoglobin production. Casgevy features precise DNA cleavage, high-fidelity gene modification, and ex vivo cell processing. Casgevy enhances treatment outcomes by enabling lasting gene correction, reducing reliance on conventional treatments, and supporting long-term clinical benefits.
Recombinant DNA Technology Market Industry Leaders And Competitive Landscape
Major companies operating in the recombinant dna technology market are Profacgen BioTech Corp, Amgen Inc, Novartis International AG, GenScript Biotech Corporation, Pfizer Inc, Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A, Merck & Co. Inc, Biogen Inc, GlaxoSmithKline PLC, New England Biolabs Inc, Bayer CropScience, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc, Gilead Sciences Inc, Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics AG, Editas Medicine Inc, bluebird bio Inc, Lonza Group AG, Horizon Discovery Group PLC, Sarepta Therapeutics Inc, Sangamo Therapeutics Inc
View The Full Recombinant DNA Technology Market Report:
Recombinant DNA Technology Market Regional Analysis And Top Geography
North America was the largest region in the recombinant DNA technology market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recombinant dna technology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
